Alnylam Pharmaceuticals, Inc.
(NASDAQ : ALNY)

( )
ALNY PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corp.
0.10%108.241.3%$1555.46m
BIIBBiogen, Inc.
-0.01%285.401.4%$826.42m
AMGNAmgen, Inc.
0.45%225.511.3%$560.39m
GILDGilead Sciences, Inc.
-0.17%64.771.0%$406.36m
VRTXVertex Pharmaceuticals, Inc.
0.03%215.071.9%$345.44m
ILMNIllumina, Inc.
1.25%314.913.5%$336.38m
REGNRegeneron Pharmaceuticals, Inc.
-0.06%344.242.6%$279.87m
EXASEXACT Sciences Corp.
0.16%83.9324.0%$220.79m
ALXNAlexion Pharmaceuticals, Inc.
-1.92%108.532.0%$184.76m
BMRNBioMarin Pharmaceutical, Inc.
-0.39%77.434.3%$134.14m
SRPTSarepta Therapeutics, Inc.
4.35%102.3014.6%$126.57m
SGENSeattle Genetics, Inc.
2.51%120.846.1%$125.11m
AAgilent Technologies, Inc.
-1.00%78.501.6%$103.06m
BGNEBeiGene Ltd.
-0.29%203.312.1%$94.15m
NBIXNeurocrine Biosciences, Inc.
0.31%113.085.0%$92.24m

Company Profile

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.